Cationic drugs and COVID-19.
Oreste Vittore BrennaSara TorrettaLorenzo PignataroFederica Di BerardinoPublished in: International journal of immunopathology and pharmacology (2020)
Given the sharp spreading of COVID-19 pandemic all around the world, our attention was brought to consider that that many cationic drugs (i.e. those characterized by the presence, at physiological pH value, of one or more cationic groups, both primary, secondary, tertiary and guanidinic aminic groups) could have any effect in impairing SARS-CoV2 entry in the host cell. This could open to new therapeutic chances against COVID-19.